Your browser doesn't support javascript.
loading
Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R; Qi, Ying; Ramsuran, Veron; Vince, Nicolas; Gao, Xiaojiang; Thomas, Rasmi; Brumme, Zabrina L; Carlson, Jonathan M; Wolinsky, Steven M; Goedert, James J; Walker, Bruce D; Segal, Florencia P; Deeks, Steven G; Haas, David W; Migueles, Stephen A; Connors, Mark; Michael, Nelson; Fellay, Jacques; Gostick, Emma; Llewellyn-Lacey, Sian; Price, David A; Lafont, Bernard A; Pymm, Phillip; Saunders, Philippa M; Widjaja, Jacqueline; Wong, Shu Cheng; Vivian, Julian P; Rossjohn, Jamie; Brooks, Andrew G; Carrington, Mary.
Afiliação
  • Martin MP; Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Naranbhai V; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
  • Shea PR; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
  • Qi Y; Institute for Genomic Medicine, Columbia University, New York, New York, USA.
  • Ramsuran V; Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Vince N; Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Gao X; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
  • Thomas R; KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Brumme ZL; Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Carlson JM; ATIP-Avenir, Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.
  • Wolinsky SM; Institut de Transplantation Urologie Néphrologie (ITUN), Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France.
  • Goedert JJ; Cancer and Inflammation Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Walker BD; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Segal FP; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
  • Deeks SG; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Haas DW; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Migueles SA; Microsoft Research, Redmond, Washington, USA.
  • Connors M; Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Michael N; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
  • Fellay J; Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA.
  • Gostick E; Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Llewellyn-Lacey S; San Francisco General Hospital Medical Center, San Francisco, California, USA.
  • Price DA; Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Lafont BA; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  • Pymm P; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
  • Saunders PM; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Widjaja J; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
  • Wong SC; School of Life Sciences, Swiss Federal Institute of Technology, Lausanne, Switzerland.
  • Vivian JP; Cardiff University School of Medicine, Heath Park, University Hospital of Wales, Cardiff, United Kingdom.
  • Rossjohn J; Non-Human Primate Immunogenetics and Cellular Immunology Unit, NIAID, NIH, Bethesda, Maryland, USA.
  • Brooks AG; Cardiff University School of Medicine, Heath Park, University Hospital of Wales, Cardiff, United Kingdom.
  • Carrington M; Non-Human Primate Immunogenetics and Cellular Immunology Unit, NIAID, NIH, Bethesda, Maryland, USA.
J Clin Invest ; 128(5): 1903-1912, 2018 05 01.
Article em En | MEDLINE | ID: mdl-29461980
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Antígenos HLA-B / Infecções por HIV / HIV-1 / Receptores KIR3DL1 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Variação Genética / Antígenos HLA-B / Infecções por HIV / HIV-1 / Receptores KIR3DL1 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article